Top-News

Pacira Biosciences Aktie News

Aktie
WKN:  A1H68T ISIN:  US6951271005 US-Symbol:  PCRX Branche:  Pharmazeutika Land:  USA
24,20 $
+0,22 $
+0,92%
20,795 € 17:56:07 Uhr
Depot/Watchlist
Marktkapitalisierung *
952,52 Mio. €
Streubesitz
-
KGV
-9,28
Index-Zuordnung
-

Pacira Biosciences News

07.02.25 - PR Newswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira PR Newswire
07.02.25 - PR Newswire
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire
06.02.25 - PR Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PR Newswire
06.02.25 - PR Newswire
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc.(PCRX) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
05.02.25 - PR Newswire
Pacira BioSciences, Inc. Stock News: Shareholder Rights Law Firm Robbins LLP Encourages PCRX Stockholders with Large Losses to Contact the Firm to Learn About Their Rights in Connection with the Class Action
Pacira BioSciences, Inc. Stock News: Shareholder Rights Law Firm Robbins LLP Encourages PCRX Stockholders with Large Losses to Contact the Firm to Learn About Their ...
04.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX ...
04.02.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX PR Newswire
03.02.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders PR Newswire
31.01.25 - PR Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PR Newswire
31.01.25 - PR Newswire
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
Investors in Pacira BioSciences, Inc. Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX PR Newswire
30.01.25 - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira PR Newswire
30.01.25 - PR Newswire
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm Notifies Shareholders of Pacira BioSciences, Inc. (PCRX) of a Class Action Lawsuit and an Upcoming Deadline PR Newswire
28.01.25 - PR Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira BioSciences, Inc. Lawsuit - PCRX PR Newswire
27.01.25 - PR Newswire
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit PR Newswire
27.01.25 - PR Newswire
Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX
Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX PR Newswire
24.01.25 - PR Newswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit ...
24.01.25 - PR Newswire
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
24.01.25 - PR Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders PR Newswire
23.01.25 - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira PR Newswire
23.01.25 - PR Newswire
Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX
Investors who lost money on Pacira BioSciences, Inc.(PCRX) should contact The Gross Law Firm about pending Class Action - PCRX PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »